Elucidating molecular mechanisms of TGF‐β‐driven transition of naïve T cells toward regulatory T‐cell phenotypes, and investigating new physiological inducers of Foxp3+ expression in CD4+ naïve or responder T cells, will enable the manipulation of specific populations of regulatory T cells in lung cancer. The gene discussed is CD4; the disease is lung carcinoma.